Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2012, Article ID 318087, 22 pages
http://dx.doi.org/10.1155/2012/318087
Review Article

Arginine-Based Inhibitors of Nitric Oxide Synthase: Therapeutic Potential and Challenges

1International Clinical Research Center-Center of Biomolecular and Cell Engineering, St. Anne's University Hospital Brno, 656 91 Brno, Czech Republic
2Institute of Biophysics, Academy of Sciences of the Czech Republic, 612 65 Brno, Czech Republic
3Department of Evolutionary Biology, University of Ferrara, 44100 Ferrara, Italy
4Department of Food and Nutrition, Kyung Hee University, Seoul 130-701, Republic of Korea

Received 2 April 2012; Accepted 30 May 2012

Academic Editor: Hidde Bult

Copyright © 2012 Jan Víteček et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. W. K. Alderton, C. E. Cooper, and R. G. Knowles, “Nitric oxide synthases: structure, function and inhibition,” Biochemical Journal, vol. 357, no. 3, pp. 593–615, 2001. View at Publisher · View at Google Scholar · View at Scopus
  2. S. Daff, “NO synthase: structures and mechanisms,” Nitric Oxide, vol. 23, no. 1, pp. 1–11, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. H. Ji, S. Tan, J. Igarashi et al., “Selective neuronal nitric oxide synthase inhibitors and the prevention of cerebral palsy,” Annals of Neurology, vol. 65, no. 2, pp. 209–217, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. J. Loscalzo and G. Welch, “Nitric oxide and its role in the cardiovascular system,” Progress in Cardiovascular Diseases, vol. 38, no. 2, pp. 87–104, 1995. View at Publisher · View at Google Scholar · View at Scopus
  5. S. R. Jaffrey and S. H. Snyder, “Nitric oxide: a neural messenger,” Annual Review of Cell and Developmental Biology, vol. 11, pp. 417–440, 1995. View at Google Scholar · View at Scopus
  6. C. Bogdan, “Nitric oxide and the immune response,” Nature Immunology, vol. 2, no. 10, pp. 907–916, 2001. View at Publisher · View at Google Scholar · View at Scopus
  7. A. J. Hobbs, A. Higgs, and S. Moncada, “Inhibition of nitric oxide synthase as a potential therapeutic target,” Annual Review of Pharmacology and Toxicology, vol. 39, pp. 191–220, 1999. View at Publisher · View at Google Scholar · View at Scopus
  8. A. C. Tinker and A. V. Wallace, “Selective inhibitors of inducible nitric oxide synthase: potential agents for the treatment of inflammatory diseases?” Current Topics in Medicinal Chemistry, vol. 6, no. 2, pp. 77–92, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. R. B. Silverman, “Design of selective neuronal nitric oxide synthase inhibitors for the prevention and treatment of neurodegenerative diseases,” Accounts of Chemical Research, vol. 42, no. 3, pp. 439–451, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. S. Madaford, S. C. Annedi, J. Ramnauth, and S. Rakhit, “Advancements in the development of nitric oxide synthase inhibitors,” in Annual Reports in Medicinal Chemistry, J. E. Macor, Ed., pp. 27–50, Elsevier, 2009. View at Google Scholar
  11. E. D. Garcin, A. S. Arvai, R. J. Rosenfeld et al., “Anchored plasticity opens doors for selective inhibitor design in nitric oxide synthase,” Nature Chemical Biology, vol. 4, no. 11, pp. 700–707, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. H. Ji, H. Li, P. Martásek, L. J. Roman, T. L. Poulos, and R. B. Silverman, “Discovery of highly potent and selective inhibitors of neuronal nitric oxide synthase by fragment hopping,” Journal of Medicinal Chemistry, vol. 52, no. 3, pp. 779–797, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. M. T. Bedford and S. G. Clarke, “Protein arginine methylation in mammals: who, what, and why,” Molecular Cell, vol. 33, no. 1, pp. 1–13, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. R. M. J. Palmer, D. D. Rees, D. S. Ashton, and S. Moncada, “L-arginine is the physiological precursor for the formation of nitric oxide in endothelium-dependent relaxation,” Biochemical and Biophysical Research Communications, vol. 153, no. 3, pp. 1251–1256, 1988. View at Google Scholar · View at Scopus
  15. I. Sakuma, D. J. Stuehr, S. S. Gross, C. Nathan, and R. Levi, “Identification of arginine as a precursor of endothelium-derived relaxing factor,” Proceedings of the National Academy of Sciences of the United States of America, vol. 85, no. 22, pp. 8664–8667, 1988. View at Google Scholar · View at Scopus
  16. K. Aisaka, S. S. Gross, O. W. Griffith, and R. Levi, “N(G)-methylarginine, an inhibitor of endothelium-derived nitric oxide synthesis, is a potent pressor agent in the guinea pig: does nitric oxide regulate blood pressure in vivo?” Biochemical and Biophysical Research Communications, vol. 160, no. 2, pp. 881–886, 1989. View at Google Scholar · View at Scopus
  17. C. J. Lowenstein, J. L. Dinerman, and S. H. Snyder, “Nitric oxide: a physiologic messenger,” Annals of Internal Medicine, vol. 120, no. 3, pp. 227–237, 1994. View at Google Scholar · View at Scopus
  18. A. Calver, J. Collier, and P. Vallance, “Nitric oxide and cardiovascular control,” Experimental Physiology, vol. 78, no. 3, pp. 303–326, 1993. View at Google Scholar · View at Scopus
  19. J. Zhang and S. H. Snyder, “Nitric-oxide in the nervous-system,” Annual Review of Pharmacology and Toxicology, vol. 35, pp. 213–233, 1995. View at Publisher · View at Google Scholar
  20. D. W. Reif and S. A. McCreedy, “N-Nitro-L-arginine and N-monomethyl-L-arginine exhibit a different pattern of inactivation toward the three nitric oxide synthases,” Archives of Biochemistry and Biophysics, vol. 320, no. 1, pp. 170–176, 1995. View at Publisher · View at Google Scholar · View at Scopus
  21. N. M. Olken, Y. Osawa, and M. A. Marletta, “Characterization of the inactivation of nitric oxide synthase by N(G)- methyl-L-arginine: evidence for heme loss,” Biochemistry, vol. 33, no. 49, pp. 14784–14791, 1994. View at Publisher · View at Google Scholar · View at Scopus
  22. O. W. Griffith and R. G. Kilbourn, “Nitric oxide synthase inhibitors: amino acids,” in Nitric Oxide, Part A: Sources and Detection of No; No Synthase, A. G. Kartsatos, Ed., vol. 268 of Methods in Enzymology, pp. 375–392, Academic Press, San Diego, 1996. View at Google Scholar
  23. K. K. McDonald, R. Rouhani, M. E. Handlogten et al., “Inhibition of endothelial cell amino acid transport System y+ by arginine analogs that inhibit nitric oxide synthase,” Biochimica et Biophysica Acta. Biomembranes, vol. 1324, no. 1, pp. 133–141, 1997. View at Publisher · View at Google Scholar · View at Scopus
  24. S. Schwartz, R. Clare, K. Devereux, and C. Fook Sheung, “Pharmacokinetics, disposition and metabolism of 546C88 (L-N(G)- methylarginine hydrochloride) in rat and dog,” Xenobiotica, vol. 27, no. 12, pp. 1259–1271, 1997. View at Publisher · View at Google Scholar · View at Scopus
  25. T. S. Maurer, Y. Mishra, and H. L. Fung, “Nonlinear pharmacokinetics of L-N-G-methyl-arginine in rats: characterization by an improved HPLC assay,” Biopharmaceutics & Drug Disposition, vol. 20, no. 8, pp. 397–400, 1999. View at Google Scholar
  26. S. I. Ueno, A. Sano, K. Kotani, K. Kondoh, and Y. Kakimoto, “Distribution of free methylarginines in rat tissues and in the bovine brain,” Journal of Neurochemistry, vol. 59, no. 6, pp. 2012–2016, 1992. View at Google Scholar · View at Scopus
  27. Z. Hussein, M. Beerahee, R. Grover et al., “Pharmacokinetics of the nitric oxide synthase inhibitor L-N(G)- methylarginine hydrochloride in patients with septic shock,” Clinical Pharmacology and Therapeutics, vol. 65, no. 1, pp. 1–9, 1999. View at Publisher · View at Google Scholar · View at Scopus
  28. J. G. Umans and R. Levi, “Nitric oxide in the regulation of blood flow and arterial pressure,” Annual Review of Physiology, vol. 57, pp. 771–790, 1995. View at Google Scholar · View at Scopus
  29. R. G. Kilbourn, A. Jubran, S. S. Gross et al., “Reversal of endotoxin-mediated shock by N(G)-methyl-L-arginine, an inhibitor of nitric oxide synthesis,” Biochemical and Biophysical Research Communications, vol. 172, no. 3, pp. 1132–1138, 1990. View at Publisher · View at Google Scholar · View at Scopus
  30. R. G. Kilbourn, S. S. Gross, A. Jubran et al., “N(G)-methyl-L-arginine inhibits tumor necrosis factor-induced hypotension: implications for the involvement of nitric oxide,” Proceedings of the National Academy of Sciences of the United States of America, vol. 87, no. 9, pp. 3629–3632, 1990. View at Publisher · View at Google Scholar · View at Scopus
  31. R. G. Kilbourn, C. Szabó, and D. L. Traber, “Beneficial versus detrimental effects of nitric oxide synthase inhibitors in circulatory shock: lessons learned from experimental and clinical studies,” Shock, vol. 7, no. 4, pp. 235–246, 1997. View at Google Scholar · View at Scopus
  32. W. G. Haynes, J. P. Noon, B. R. Walker, and D. J. Webb, “Inhibition of nitric oxide synthesis increases blood pressure in healthy humans,” Journal of Hypertension, vol. 11, no. 12, pp. 1375–1380, 1993. View at Google Scholar · View at Scopus
  33. J. S. Stamler, E. Loh, M. A. Roddy, K. E. Currie, and M. A. Creager, “Nitric oxide regulates basal systemic and pulmonary vascular resistance in healthy humans,” Circulation, vol. 89, no. 5, pp. 2035–2040, 1994. View at Google Scholar · View at Scopus
  34. M. Nyberg, S. P. Mortensen, B. Saltin, Y. Hellsten, and J. Bangsbo, “Low blood flow at onset of moderate-intensity exercise does not limit muscle oxygen uptake,” American Journal of Physiology - Regulatory Integrative and Comparative Physiology, vol. 298, no. 3, pp. R843–R848, 2010. View at Publisher · View at Google Scholar · View at Scopus
  35. A. Petros, D. Bennett, and P. Vallance, “Effect of nitric oxide synthase inhibitors on hypotension in patients with septic shock,” Lancet, vol. 338, no. 8782-8783, pp. 1557–1558, 1991. View at Google Scholar · View at Scopus
  36. A. Petros, G. Lamb, A. Leone, S. Moncada, D. Bennett, and P. Vallance, “Effects of a nitric oxide synthase inhibitor in human with septic shock,” Cardiovascular Research, vol. 28, no. 1, pp. 34–39, 1994. View at Google Scholar · View at Scopus
  37. R. Grover, D. Zaccardelli, G. Colice, K. Guntupalli, D. Watson, and J. L. Vincent, “An open-label dose escalation study of the nitric oxide synthase inhibitor, N(G)-methyl-L-arginine hydrochloride (546C88), in patients with septic shock,” Critical Care Medicine, vol. 27, no. 5, pp. 913–922, 1999. View at Publisher · View at Google Scholar · View at Scopus
  38. J. Bakker, R. Grover, A. McLuckie et al., “Administration of the nitric oxide synthase inhibitor NG-methyl- L-arginine hydrochloride (546C88) by intravenous infusion for up to 72 hours can promote the resolution of shock in patients with severe sepsis: results of a randomized, double-blind, placebo-controlled multicenter study (study no. 144-002),” Critical Care Medicine, vol. 32, no. 1, pp. 1–12, 2004. View at Google Scholar · View at Scopus
  39. D. Watson, R. Grover, A. Anzueto et al., “Cardiovascular effects of the nitric oxide synthase inhibitor N G-methyl-L-arginine hydrochloride (546C88) in patients with septic shock: results of a randomized, double-blind, placebo-controlled multicenter study (study no. 144-002),” Critical Care Medicine, vol. 32, no. 1, pp. 13–20, 2004. View at Google Scholar · View at Scopus
  40. A. López, J. A. Lorente, J. Steingrub et al., “Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock,” Critical Care Medicine, vol. 32, no. 1, pp. 21–30, 2004. View at Google Scholar · View at Scopus
  41. L. H. Lassen, M. Ashina, I. Christiansen et al., “Nitric oxide synthase inhibition: a new principle in the treatment of migraine attacks,” Cephalalgia, vol. 18, no. 1, pp. 27–32, 1998. View at Publisher · View at Google Scholar · View at Scopus
  42. M. Ashina, L. H. Lassen, L. Bendtsen, R. Jensen, and J. Olesen, “Effect of inhibition of nitric oxide synthase on chronic tension-type headache: a randomised crossover trial,” Lancet, vol. 353, no. 9149, pp. 287–289, 1999. View at Publisher · View at Google Scholar · View at Scopus
  43. L. H. Lassen, I. Christiansen, H. K. Iversen, I. Jansen-Olesen, and J. Olesen, “The effect of nitric oxide synthase inhibition on histamine induced headache and arterial dilatation in migraineurs,” Cephalalgia, vol. 23, no. 9, pp. 877–886, 2003. View at Publisher · View at Google Scholar · View at Scopus
  44. L. Hjorth Lassen, H. Klingenberg Iversen, and J. Olesen, “A dose-response study of nitric oxide synthase inhibition in different vascular beds in man,” European Journal of Clinical Pharmacology, vol. 59, no. 7, pp. 499–505, 2003. View at Publisher · View at Google Scholar · View at Scopus
  45. L. H. Lassen, B. Sperling, A. R. Andersen, and J. Olesen, “The effect of i.v. L-NG methylarginine hydrochloride (L-NMMA: 546C88) on basal and acetazolamide (Diamox) induced changes of blood velocity in cerebral arteries and regional cerebral blood flow in man,” Cephalalgia, vol. 25, no. 5, pp. 344–352, 2005. View at Publisher · View at Google Scholar · View at Scopus
  46. P. Vallance, A. Leone, A. Calver, J. Collier, and S. Moncada, “Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure,” Lancet, vol. 339, no. 8793, pp. 572–575, 1992. View at Publisher · View at Google Scholar · View at Scopus
  47. P. Vallance, A. Leone, A. Calver, J. Collier, and S. Moncada, “Endogenous dimethylarginine as an inhibitor of nitric oxide synthesis,” Journal of Cardiovascular Pharmacology, vol. 20, no. 12, pp. S60–S62, 1992. View at Google Scholar · View at Scopus
  48. R. H. Böger, “Asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, explains the "L-arginine paradox" and acts as a novel cardiovascular risk factor,” Journal of Nutrition, vol. 134, no. 10, pp. S2842–S2847, 2004. View at Google Scholar · View at Scopus
  49. Y. Komori, G. C. Wallace, and J. M. Fukuto, “Inhibition of purified nitric oxide synthase from rat cerebellum and macrophage by L-arginine analogs,” Archives of Biochemistry and Biophysics, vol. 315, no. 2, pp. 213–218, 1994. View at Publisher · View at Google Scholar · View at Scopus
  50. A. J. Cardounel and J. L. Zweier, “Endogenous methylarginines regulate neuronal nitric-oxide synthase and prevent excitotoxic injury,” Journal of Biological Chemistry, vol. 277, no. 37, pp. 33995–34002, 2002. View at Publisher · View at Google Scholar · View at Scopus
  51. J. T. Kielstein and C. Zoccali, “Asymmetric dimethylarginine: a cardiovascular risk factor and a uremic toxin coming of age?” American Journal of Kidney Diseases, vol. 46, no. 2, pp. 186–202, 2005. View at Publisher · View at Google Scholar · View at Scopus
  52. R. H. Böger, “The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor,” Cardiovascular Research, vol. 59, no. 4, pp. 824–833, 2003. View at Publisher · View at Google Scholar · View at Scopus
  53. T. Teerlink, Z. Luo, F. Palm, and C. S. Wilcox, “Cellular ADMA: regulation and action,” Pharmacological Research, vol. 60, no. 6, pp. 448–460, 2009. View at Publisher · View at Google Scholar · View at Scopus
  54. P. Vallance and J. Leiper, “Cardiovascular biology of the asymmetric dimethylarginine:dimethylarginine dimethylaminohydrolase pathway,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 24, no. 6, pp. 1023–1030, 2004. View at Publisher · View at Google Scholar · View at Scopus
  55. S. S. Wolf, “The protein arginine methyltransferase family: an update about function, new perspectives and the physiological role in humans,” Cellular and Molecular Life Sciences, vol. 66, no. 13, pp. 2109–2121, 2009. View at Publisher · View at Google Scholar · View at Scopus
  56. P. K. Moore, O. A. Al-Swayeh, N. W. S. Chong, R. A. Evans, and A. Gibson, “L-N(G)-nitro arginine (L-NOARG), a novel, L-arginine-reversible inhibitor of endothelium-dependent vasodilatation in vitro,” British Journal of Pharmacology, vol. 99, no. 2, pp. 408–412, 1990. View at Google Scholar · View at Scopus
  57. D. D. Rees, R. M. J. Palmer, R. Schulz, H. F. Hodson, and S. Moncada, “Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo,” British Journal of Pharmacology, vol. 101, no. 3, pp. 746–752, 1990. View at Google Scholar · View at Scopus
  58. E. S. Furfine, “Selective inhibition of constitutive nitric oxide synthase by L-NG-nitroarginine,” Biochemistry, vol. 32, no. 33, pp. 8512–8517, 1993. View at Google Scholar · View at Scopus
  59. W. M. Moore, R. K. Webber, K. F. Fok et al., “Inhibitors of human nitric oxide synthase isoforms with the carbamidine moiety as a common structural element,” Bioorganic and Medicinal Chemistry, vol. 4, no. 9, pp. 1559–1564, 1996. View at Publisher · View at Google Scholar · View at Scopus
  60. E. S. Furfine, M. F. Harmon, J. E. Paith et al., “Potent and selective inhibition of human nitric oxide synthases. Selective inhibition of neuronal nitric oxide synthase by S-methyl-L-thiocitrulline and S-ethyl-L-thiocitrulline,” Journal of Biological Chemistry, vol. 269, no. 43, pp. 26677–26683, 1994. View at Google Scholar · View at Scopus
  61. P. Klatt, K. Schmidt, F. Brunner, and B. Mayer, “Inhibitors of brain nitric oxide synthase. Binding kinetics, metabolism, and enzyme inactivation,” Journal of Biological Chemistry, vol. 269, no. 3, pp. 1674–1680, 1994. View at Google Scholar · View at Scopus
  62. K. Schmidt, P. Klatt, and B. Mayer, “Characterization of endothelial cell amino acid transport systems involved in the actions of nitric oxide synthase inhibitors,” Molecular Pharmacology, vol. 44, no. 3, pp. 615–621, 1993. View at Google Scholar · View at Scopus
  63. P. Kubes, M. Suzuki, and D. N. Granger, “Nitric oxide: an endogenous modulator of leukocyte adhesion,” Proceedings of the National Academy of Sciences of the United States of America, vol. 88, no. 11, pp. 4651–4655, 1991. View at Google Scholar · View at Scopus
  64. V. L. Dawson, T. M. Dawson, D. A. Bartley, G. R. Uhl, and S. H. Snyder, “Mechanisms of nitric oxide-mediated neurotoxicity in primary brain cultures,” Journal of Neuroscience, vol. 13, no. 6, pp. 2651–2661, 1993. View at Google Scholar · View at Scopus
  65. K. M. Boje and P. K. Arora, “Microglial-produced nitric oxide and reactive nitrogen oxides mediate neuronal cell death,” Brain Research, vol. 587, no. 2, pp. 250–256, 1992. View at Publisher · View at Google Scholar · View at Scopus
  66. A. Papapetropoulos, G. García-Cardeña, J. A. Madri, and W. C. Sessa, “Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells,” Journal of Clinical Investigation, vol. 100, no. 12, pp. 3131–3139, 1997. View at Google Scholar · View at Scopus
  67. M. Ziche, L. Morbidelli, E. Masini et al., “Nitric oxide mediates angiogenesis in vivo and endothelial cell growth and migration in vitro promoted by substance P,” Journal of Clinical Investigation, vol. 94, no. 5, pp. 2036–2044, 1994. View at Google Scholar · View at Scopus
  68. J. L. Balligand, R. A. Kelly, P. A. Marsden, T. W. Smith, and T. Michel, “Control of cardiac muscle cell function by an endogenous nitric oxide signaling system,” Proceedings of the National Academy of Sciences of the United States of America, vol. 90, no. 1, pp. 347–351, 1993. View at Publisher · View at Google Scholar · View at Scopus
  69. M. A. Tabrizi-Fard and H. L. Fung, “Pharmacokinetics and steady-state tissue distribution of L- and D-isomers of nitroarginine in rats,” Drug Metabolism and Disposition, vol. 24, no. 11, pp. 1241–1246, 1996. View at Google Scholar · View at Scopus
  70. E. J. Kidd, A. D. Michel, and P. P. A. Humphrey, “Autoradiographic distribution of [3H]L-N(G)-Nitro-arginine binding in rat brain,” Neuropharmacology, vol. 34, no. 1, pp. 63–73, 1995. View at Publisher · View at Google Scholar · View at Scopus
  71. V. L. R. Rao and R. F. Butterworth, “Kinetics, pharmacology, and autoradiographic distribution of L-[3H]nitroarginine binding sites in rat cerebellum,” Journal of Neurochemistry, vol. 66, no. 2, pp. 701–709, 1996. View at Google Scholar · View at Scopus
  72. S. Pfeiffer, E. Leopold, K. Schmidt, F. Brunner, and B. Mayer, “Inhibition of nitric oxide synthesis by N(G)-nitro-L-arginine methyl ester (L-NAME): requirement for bioactivation to the free acid, N(G)-nitro-L-arginine,” British Journal of Pharmacology, vol. 118, no. 6, pp. 1433–1440, 1996. View at Google Scholar · View at Scopus
  73. U. Frandsen, J. Bangsbo, M. Sander et al., “Exercise-induced hyperaemia and leg oxygen uptake are not altered during effective inhibition of nitric oxide synthase with NG-nitro-L-arginine methyl ester in humans,” Journal of Physiology, vol. 531, no. 1, pp. 257–264, 2001. View at Publisher · View at Google Scholar · View at Scopus
  74. J. A. M. Avontuur, S. L. C. E. Buijk, and H. A. Bruining, “Distribution and metabolism of N(G)-nitro-L-arginine methyl ester in patients with septic shock,” European Journal of Clinical Pharmacology, vol. 54, no. 8, pp. 627–631, 1998. View at Publisher · View at Google Scholar · View at Scopus
  75. H. Q. Zhang, W. Fast, M. A. Marletta, P. Martasek, and R. B. Silverman, “Potent and selective inhibition of neuronal nitric oxide synthase by N(ω)-propyl-L-arginine,” Journal of Medicinal Chemistry, vol. 40, no. 24, pp. 3869–3870, 1997. View at Publisher · View at Google Scholar · View at Scopus
  76. H. Q. Zhang, R. P. Dixon, M. A. Marletta, D. Nikolic, R. Van Breemen, and R. B. Silverman, “Mechanism of inactivation of neuronal nitric oxide synthase by N(ω)-allyl-L-arginine,” Journal of the American Chemical Society, vol. 119, no. 45, pp. 10888–10902, 1997. View at Publisher · View at Google Scholar · View at Scopus
  77. N. M. Olken and M. A. Marietta, “NG-allyl- and NG-cyclopropyl-L-arginine: two novel inhibitors of macrophage nitric oxide synthase,” Journal of Medicinal Chemistry, vol. 35, no. 6, pp. 1137–1144, 1992. View at Google Scholar · View at Scopus
  78. D. J. Wolff and A. Lubeskie, “Inactivation of nitric oxide synthase isoforms by diaminoguanidine and NG-amino-L-arginine,” Archives of Biochemistry and Biophysics, vol. 325, no. 2, pp. 227–234, 1996. View at Publisher · View at Google Scholar · View at Scopus
  79. H. Huang, P. Martasek, L. J. Roman, B. S. S. Masters, and R. B. Silverman, “N(ω)-nitroarginine-containing dipeptide amides. Potent and highly selective inhibitors of neuronal nitric oxide synthase,” Journal of Medicinal Chemistry, vol. 42, no. 16, pp. 3147–3153, 1999. View at Publisher · View at Google Scholar · View at Scopus
  80. R. B. Silverman, H. Huang, M. A. Marletta, and P. Martasek, “Selective inhibition of neuronal nitric oxide synthase by N(ω)- nitroarginine- and phenylalanine-containing dipeptides and dipeptide esters,” Journal of Medicinal Chemistry, vol. 40, no. 18, pp. 2813–2817, 1997. View at Publisher · View at Google Scholar · View at Scopus
  81. H. Ji, J. A. Gómez-Vidal, P. Martásek, L. J. Roman, and R. B. Silverman, “Conformationally restricted dipeptide amides as potent and selective neuronal nitric oxide synthase inhibitors,” Journal of Medicinal Chemistry, vol. 49, no. 21, pp. 6254–6263, 2006. View at Publisher · View at Google Scholar · View at Scopus
  82. J. M. Hah, L. J. Roman, P. Martásek, and R. B. Silverman, “Reduced amide bond peptidomimetics. (4S)-N-(4-amino-5-[aminoalkyl]aminopentyl)-N′-nitroguanidines, potent and highly selective inhibitors of neuronal nitric oxide synthase,” Journal of Medicinal Chemistry, vol. 44, no. 16, pp. 2667–2670, 2001. View at Publisher · View at Google Scholar · View at Scopus
  83. J. M. Hah, P. Martásek, L. J. Roman, and R. B. Silverman, “Aromatic reduced amide bond peptidomimetics as selective inhibitors of neuronal nitric oxide synthase,” Journal of Medicinal Chemistry, vol. 46, no. 9, pp. 1661–1669, 2003. View at Publisher · View at Google Scholar · View at Scopus
  84. J. M. Park, T. Higuchi, K. Kikuchi et al., “Selective inhibition of human inducible nitric oxide synthase by S-alkyl-L-isothiocitrulline-containing dipeptides,” British Journal of Pharmacology, vol. 132, no. 8, pp. 1876–1882, 2001. View at Google Scholar · View at Scopus
  85. B. R. Babu and O. W. Griffith, “N5-(1-imino-3-butenyl)-L-ornithine. A neuronal isoform selective mechanism-based inactivator of nitric oxide synthase,” Journal of Biological Chemistry, vol. 273, no. 15, pp. 8882–8889, 1998. View at Publisher · View at Google Scholar · View at Scopus
  86. E. A. Litzinger, P. Martásek, L. J. Roman, and R. B. Silverman, “Design, synthesis, and biological testing of potential heme-coordinating nitric oxide synthase inhibitors,” Bioorganic and Medicinal Chemistry, vol. 14, no. 9, pp. 3185–3198, 2006. View at Publisher · View at Google Scholar · View at Scopus
  87. R. J. Young, R. M. Beams, K. Carter et al., “Inhibition of inducible nitric oxide synthase by acetamidine derivatives of hetero-substituted lysine and homolysine,” Bioorganic and Medicinal Chemistry Letters, vol. 10, no. 6, pp. 597–600, 2000. View at Publisher · View at Google Scholar · View at Scopus
  88. W. K. Alderton, A. D. R. Angell, C. Craig et al., “GW274150 and GW273629 are potent and highly selective inhibitors of inducible nitric oxide synthase in vitro and in vivo,” British Journal of Pharmacology, vol. 145, no. 3, pp. 301–312, 2005. View at Publisher · View at Google Scholar · View at Scopus
  89. R. Ijuin, N. Umezawa, and T. Higuchi, “Design, synthesis, and evaluation of new type of l-amino acids containing pyridine moiety as nitric oxide synthase inhibitor,” Bioorganic and Medicinal Chemistry, vol. 14, no. 10, pp. 3563–3570, 2006. View at Publisher · View at Google Scholar · View at Scopus
  90. S. Ulhaq, E. C. Chinje, M. A. Naylor, M. Jaffar, I. J. Stratford, and M. D. Threadgill, “S-2-Amino-5-azolylpentanoic acids related to L-ornithine as inhibitors of the isoforms of nitric oxide synthase (NOS),” Bioorganic and Medicinal Chemistry, vol. 6, no. 11, pp. 2139–2149, 1998. View at Publisher · View at Google Scholar · View at Scopus
  91. S. Ulhaq, E. C. Chinje, M. A. Naylor, M. Jaffar, I. J. Stratford, and M. D. Threadgill, “Heterocyclic analogues of L-citrulline as inhibitors of the isoforms of nitric oxide synthase (NOS) and identification of N(δ)-(4,5-dihydrothiazol-2-yl)ornithine as a potent inhibitor,” Bioorganic and Medicinal Chemistry, vol. 7, no. 9, pp. 1787–1796, 1999. View at Publisher · View at Google Scholar · View at Scopus
  92. M. Scheer, A. Grote, A. Chang et al., “BRENDA, the enzyme information system in 2011,” Nucleic Acids Research, vol. 39, no. 1, pp. D670–D676, 2011. View at Publisher · View at Google Scholar · View at Scopus
  93. B. R. Babu and O. W. Griffith, “Design of isoform-selective inhibitors of nitric oxide synthase,” Current Opinion in Chemical Biology, vol. 2, no. 4, pp. 491–500, 1998. View at Google Scholar · View at Scopus
  94. E. P. Garvey, J. A. Oplinger, G. J. Tanoury et al., “Potent and selective inhibition of human nitric oxide synthases. Inhibition by non-amino acid isothioureas,” Journal of Biological Chemistry, vol. 269, no. 43, pp. 26669–26676, 1994. View at Google Scholar · View at Scopus
  95. T. J. Hagen, A. A. Bergmanis, S. W. Kramer et al., “2-Iminopyrrolidines as potent and selective inhibitors of human inducible nitric oxide synthase,” Journal of Medicinal Chemistry, vol. 41, no. 19, pp. 3675–3683, 1998. View at Publisher · View at Google Scholar · View at Scopus
  96. J. L. Collins, B. G. Shearer, J. A. Oplinger et al., “N-phenylamidines as selective inhibitors of human neuronal nitric oxide synthase: structure-activity studies and demonstration of in vivo activity,” Journal of Medicinal Chemistry, vol. 41, no. 15, pp. 2858–2871, 1998. View at Publisher · View at Google Scholar · View at Scopus
  97. J. Seo, P. Martásek, L. J. Roman, and R. B. Silverman, “Selective l-nitroargininylaminopyrrolidine and l-nitroargininylaminopiperidine neuronal nitric oxide synthase inhibitors,” Bioorganic and Medicinal Chemistry, vol. 15, no. 5, pp. 1928–1938, 2007. View at Publisher · View at Google Scholar · View at Scopus
  98. M. Sonntag, A. Deussen, and J. Schrader, “Role of nitric oxide in local blood flow control in the anaesthetized dog,” Pflugers Archiv European Journal of Physiology, vol. 420, no. 2, pp. 194–199, 1992. View at Google Scholar · View at Scopus
  99. G. A. Van Buren, D. Yang, and K. E. Clark, “Estrogen-induced uterine vasodilatation is antagonized by L-nitroarginine methyl ester, an inhibitor of nitric oxide synthesis,” American Journal of Obstetrics and Gynecology, vol. 167, no. 3, pp. 828–833, 1992. View at Google Scholar · View at Scopus
  100. A. Vials and G. Burnstock, “Effects of nitric oxide synthase inhibitors, L-N(G)-nitroarginine and L-N(G)-nitroarginine methyl ester, on responses to vasodilators of the guinea-pig coronary vasculature,” British Journal of Pharmacology, vol. 107, no. 2, pp. 604–609, 1992. View at Google Scholar · View at Scopus
  101. J. A. Lorente, L. Landin, R. De Pablo, E. Renes, and D. Liste, “L-arginine pathway in the sepsis syndrome,” Critical Care Medicine, vol. 21, no. 9, pp. 1287–1295, 1993. View at Google Scholar · View at Scopus
  102. J. A. M. Avontuur, R. P. Tutein Nolthenius, J. W. Van Bodegom, and H. A. Bruining, “Prolonged inhibition of nitric oxide synthesis in severe septic shock: a clinical study,” Critical Care Medicine, vol. 26, no. 4, pp. 660–667, 1998. View at Publisher · View at Google Scholar · View at Scopus
  103. D. H. Yates, S. A. Kharitonov, P. S. Thomas, and P. J. Barnes, “Endogenous nitric oxide is decreased in asthmatic patients by an inhibitor of inducible nitric oxide synthase,” American Journal of Respiratory and Critical Care Medicine, vol. 154, no. 1, pp. 247–250, 1996. View at Google Scholar · View at Scopus
  104. W. Fast, M. E. Levsky, M. A. Marletta, and R. B. Silverman, “N(ω)-Propargyl-L-arginine and N(ω)-hydroxy-N(ω)-propargyl-L-arginine are inhibitors, but not activators, of neuronal and macrophage nitric oxide synthases,” Bioorganic and Medicinal Chemistry, vol. 5, no. 8, pp. 1601–1608, 1997. View at Publisher · View at Google Scholar · View at Scopus
  105. C. Raoul, A. G. Estévez, H. Nishimune et al., “Motoneuron death triggered by a specific pathway downstream of fas: potentiation by ALS-linked SOD1 mutations,” Neuron, vol. 35, no. 6, pp. 1067–1083, 2002. View at Publisher · View at Google Scholar · View at Scopus
  106. M. H. Caron and C. Alling, “Role of nitric oxide in ethanol-induced up-regulation of muscarinic acetylcholine receptors in SH-SY5Y cells,” Alcoholism: Clinical and Experimental Research, vol. 25, no. 8, pp. 1107–1113, 2001. View at Google Scholar · View at Scopus
  107. G. R. Cooper, K. Mialkowski, and D. J. Wolff, “Cellular and enzymatic studies of N(ω)-propyl-L-arginine and S-ethyl-N- [4-(trifluoromethyl)phenyl]isothiourea as reversible, slowly dissociating inhibitors selective for the neuronal nitric oxide synthase isoform,” Archives of Biochemistry and Biophysics, vol. 375, no. 1, pp. 183–194, 2000. View at Publisher · View at Google Scholar · View at Scopus
  108. D. Oceandy, E. J. Cartwright, M. Emerson et al., “Neuronal nitric oxide synthase signaling in the heart is regulated by the sarcolemmal calcium pump 4b,” Circulation, vol. 115, no. 4, pp. 483–492, 2007. View at Publisher · View at Google Scholar · View at Scopus
  109. A. Isaak and J. Ellrich, “Neuronal nitric oxide synthase is involved in the induction of nerve growth factor-induced neck muscle nociception,” Headache, vol. 51, no. 5, pp. 734–743, 2011. View at Publisher · View at Google Scholar · View at Scopus
  110. D. Klamer, J. A. Engel, and L. Svensson, “The neuronal selective nitric oxide synthase inhibitor, N ω-propyl-l-arginine, blocks the effects of phencyclidine on prepulse inhibition and locomotor activity in mice,” European Journal of Pharmacology, vol. 503, no. 1–3, pp. 103–107, 2004. View at Publisher · View at Google Scholar · View at Scopus
  111. D. L. Kellogg, J. L. Zhao, and Y. Wu, “Roles of nitric oxide synthase isoforms in cutaneous vasodilation induced by local warming of the skin and whole body heat stress in humans,” Journal of Applied Physiology, vol. 107, no. 5, pp. 1438–1444, 2009. View at Publisher · View at Google Scholar · View at Scopus
  112. J. M. Fukuto, K. S. Wood, R. E. Byrns, and L. J. Ignarro, “N(G)-Amino-L-arginine: a new potent antagonist of L-arginine-mediated endothelium-dependent relaxation,” Biochemical and Biophysical Research Communications, vol. 168, no. 2, pp. 458–465, 1990. View at Publisher · View at Google Scholar · View at Scopus
  113. S. S. Gross, D. J. Stuehr, K. Aisaka, E. A. Jaffe, R. Levi, and O. W. Griffith, “Macrophage and endothelial cell nitric oxide synthesis: cell-type selective inhibition by N(G)-aminoarginine, N(G)-nitroarginine and N(G)-methylarginine,” Biochemical and Biophysical Research Communications, vol. 170, no. 1, pp. 96–103, 1990. View at Publisher · View at Google Scholar · View at Scopus
  114. M. Hecker, D. T. Walsh, and J. R. Vane, “On the substrate specificity of nitric oxide synthase,” FEBS Letters, vol. 294, no. 3, pp. 221–224, 1991. View at Publisher · View at Google Scholar · View at Scopus
  115. R. B. Silverman, H. Huang, and H. Q. Zhang, “Inhibition of nitric oxide synthase by amino acids and dipeptides,” USA patent US6274557B1, Northwestern University, Evanston, Ill, USA, 2001.
  116. R. B. Silverman, “Selective neuronal nitric oxide synthase inhibitors,” USA patent WO03000198(A2), Northwestern University, 2003.
  117. N. Kobayashi, T. Higuchi, M. Hirobe, and T. Nagano, “Selective inhibitor for nitrogen monooxide synthase,” Dainippon Pharmaceutical, Japan patent JP10237097(A), 1998.
  118. N. Kobayashi, T. Higuchi, Y. Urano, K. Kikuchi, M. Hirobe, and T. Nagano, “Dipeptides containing L-arginine analogs: new isozyme-selective inhibitors of nitric oxide synthase,” Biological and Pharmaceutical Bulletin, vol. 22, no. 9, pp. 936–940, 1999. View at Google Scholar · View at Scopus
  119. N. E. Rogers and L. J. Ignarro, “Constitutive nitric oxide synthase from cerebellum is reversibly inhibited by nitric oxide formed from L-arginine,” Biochemical and Biophysical Research Communications, vol. 189, no. 1, pp. 242–249, 1992. View at Publisher · View at Google Scholar · View at Scopus
  120. K. Narayanan and O. W. Griffith, “Synthesis of L-thiocitrulline, L-homothiocitrulline, and S-methyl-L-thiocitrulline: a new class of potent nitric oxide synthase inhibitors,” Journal of Medicinal Chemistry, vol. 37, no. 7, pp. 885–887, 1994. View at Google Scholar · View at Scopus
  121. C. Frey, K. Narayanan, K. McMillan et al., “L-thiocitrulline: a stereospecific, heme-binding inhibitor of nitric- oxide synthases,” Journal of Biological Chemistry, vol. 269, no. 42, pp. 26083–26091, 1994. View at Google Scholar · View at Scopus
  122. K. Narayanan, L. Spack, K. McMillan et al., “S-alkyl-L-thiocitrullines. Potent stereoselective inhibitors of nitric oxide synthase with strong pressor activity in vivo,” Journal of Biological Chemistry, vol. 270, no. 19, pp. 11103–11110, 1995. View at Publisher · View at Google Scholar · View at Scopus
  123. R. Ijuin, N. Umezawa, S. I. Nagai, and T. Higuchi, “Evaluation of 3-substituted arginine analogs as selective inhibitors of human nitric oxide synthase isozymes,” Bioorganic and Medicinal Chemistry Letters, vol. 15, no. 11, pp. 2881–2885, 2005. View at Publisher · View at Google Scholar · View at Scopus
  124. J. Zhang, M. Xu, C. S. Dence, E. L. C. Sherman, T. J. McCarthy, and M. J. Welch, “Synthesis, in vivo evaluation and PET study of a carbon-11 -labeled neuronal nitric oxide synthase (nNOS) inhibitor S-Methyl-L-thiocitrulline,” Journal of Nuclear Medicine, vol. 38, no. 8, pp. 1273–1278, 1997. View at Google Scholar · View at Scopus
  125. J. Zanzinger, J. Czachurski, and H. Seller, “Neuronal nitric oxide reduces sympathetic excitability by modulation of central glutamate effects in pigs,” Circulation Research, vol. 80, no. 4, pp. 565–571, 1997. View at Google Scholar · View at Scopus
  126. J. B. Kelley, K. L. Anderson, S. L. Altmann, and Y. Itzhak, “Long-term memory of visually cued fear conditioning: roles of the neuronal nitric oxide synthase gene and cyclic AMP response element-binding protein,” Neuroscience, vol. 174, pp. 91–103, 2011. View at Publisher · View at Google Scholar · View at Scopus
  127. A. Ichihara, E. W. Inscho, J. D. Imig, and L. G. Navar, “Neuronal nitric oxide synthase modulates rat renal microvascular function,” American Journal of Physiology, Renal Physiology, vol. 274, no. 3, pp. F516–F524, 1998. View at Google Scholar · View at Scopus
  128. R. Komers, T. T. Oyama, J. G. Chapman, K. M. Allison, and S. Anderson, “Effects of systemic inhibition of neuronal nitric oxide synthase in diabetic rats,” Hypertension, vol. 35, no. 2, pp. 655–661, 2000. View at Google Scholar · View at Scopus
  129. R. Komers, J. N. Lindsley, T. T. Oyama, K. M. Allison, and S. Anderson, “Role of neuronal nitric oxide synthase (NOS1) in the pathogenesis of renal hemodynamic changes in diabetes,” American Journal of Physiology, Renal Physiology, vol. 279, no. 3, pp. F573–F583, 2000. View at Google Scholar · View at Scopus
  130. T. B. McCall, M. Feelisch, R. M. J. Palmer, and S. Moncada, “Identification of N-iminoethyl-L-ornithine as an irreversible inhibitor of nitric oxide synthase in phagocytic cells,” British Journal of Pharmacology, vol. 102, no. 1, pp. 234–238, 1991. View at Google Scholar · View at Scopus
  131. W. M. Moore, R. K. Webber, G. M. Jerome, F. S. Tjoeng, T. P. Misko, and M. G. Currie, “L-N6-(1-Iminoethyl)lysine: a selective inhibitor of inducible nitric oxide synthase,” Journal of Medicinal Chemistry, vol. 37, no. 23, pp. 3886–3888, 1994. View at Google Scholar · View at Scopus
  132. E. A. Hallinan, S. Tsymbalov, C. R. Dorn et al., “Synthesis and biological characterization of L-N6-(1-iminoethyl)lysine 5-tetrazole-amide, a prodrug of a selective iNOS inhibitor,” Journal of Medicinal Chemistry, vol. 45, no. 8, pp. 1686–1689, 2002. View at Publisher · View at Google Scholar · View at Scopus
  133. J. Assreuy, F. Q. Cunha, M. Epperlein et al., “Production of nitric oxide and superoxide by activated macrophages and killing of Leishmania major,” European Journal of Immunology, vol. 24, no. 3, pp. 672–676, 1994. View at Google Scholar · View at Scopus
  134. J. C. De Graaf, J. D. Banga, S. Moncada, R. M. J. Palmer, P. G. De Groot, and J. J. Sixma, “Nitric oxide functions as an inhibitor of platelet adhesion under flow conditions,” Circulation, vol. 85, no. 6, pp. 2284–2290, 1992. View at Google Scholar · View at Scopus
  135. D. C. Jenkins, I. G. Charles, L. L. Thomsen et al., “Roles of nitric oxide in tumor growth,” Proceedings of the National Academy of Sciences of the United States of America, vol. 92, no. 10, pp. 4392–4396, 1995. View at Google Scholar · View at Scopus
  136. J. S. Duffield, L. P. Erwig, X. Q. Wei, F. Y. Liew, A. J. Rees, and J. S. Savill, “Activated macrophages direct apoptosis and suppress mitosis of mesangial cells,” Journal of Immunology, vol. 164, no. 4, pp. 2110–2119, 2000. View at Google Scholar · View at Scopus
  137. S. Brahmachari, Y. K. Fung, and K. Pahan, “Induction of glial fibrillary acidic protein expression in astrocytes by nitric oxide,” Journal of Neuroscience, vol. 26, no. 18, pp. 4930–4939, 2006. View at Publisher · View at Google Scholar · View at Scopus
  138. J. Y. Zhang, Y. Wang, M. N. Milton, L. Kraus, A. P. Breau, and S. K. Paulson, “Disposition and Pharmacokinetics of L-N6-(1-Iminoethyl)Lysine-5-Tetrazole-Amide, a Selective iNOS Inhibitor, in Rats,” Journal of Pharmaceutical Sciences, vol. 93, no. 5, pp. 1229–1240, 2004. View at Publisher · View at Google Scholar · View at Scopus
  139. J. Y. Zhang, Y. F. Wang, M. N. Milton et al., “Pharmacokinetics, metabolism and excretion of an inhibitor of inducible nitric oxide synthase, L-NIL-TA, in dog,” Xenobiotica, vol. 33, no. 11, pp. 1159–1171, 2003. View at Publisher · View at Google Scholar · View at Scopus
  140. F. László and B. J. R. Whittle, “Actions of isoform-selective and non-selective nitric oxide synthase inhibitors on endotoxin-induced vascular leakage in rat colon,” European Journal of Pharmacology, vol. 334, no. 1, pp. 99–102, 1997. View at Publisher · View at Google Scholar · View at Scopus
  141. J. R. Connor, P. T. Manning, S. L. Settle et al., “Suppression of adjuvant-induced arthritis by selective inhibition of inducible nitric oxide synthase,” European Journal of Pharmacology, vol. 273, no. 1-2, pp. 15–24, 1995. View at Publisher · View at Google Scholar · View at Scopus
  142. J. D. Macmicking, R. J. North, R. Lacourse, J. S. Mudgett, S. K. Shah, and C. F. Nathan, “Identification of nitric oxide synthase as a protective locus against tuberculosis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 10, pp. 5243–5248, 1997. View at Publisher · View at Google Scholar · View at Scopus
  143. D. Salvemini, Z. Q. Wang, P. S. Wyatt et al., “Nitric oxide: a key mediator in the early and late phase of carrageenan-induced rat paw inflammation,” British Journal of Pharmacology, vol. 118, no. 4, pp. 829–838, 1996. View at Google Scholar · View at Scopus
  144. J. P. Pelletier, D. Jovanovic, J. C. Fernandes et al., “Reduced progression of experimental osteoarthritis in vivo by selective inhibition of inducible nitric oxide synthase,” Arthritis & Rheumatism, vol. 41, no. 7, pp. 1275–1286, 1998. View at Publisher · View at Google Scholar
  145. M. Dumont, E. Wille, N. Y. Calingasan, C. Nathan, M. F. Beal, and M. T. Lin, “N-iminoethyl-l-lysine improves memory and reduces amyloid pathology in a transgenic mouse model of amyloid deposition,” Neurochemistry International, vol. 56, no. 2, pp. 345–351, 2010. View at Publisher · View at Google Scholar · View at Scopus
  146. J. A. Crowell, V. E. Steele, C. C. Sigman, and J. R. Fay, “Is inducible nitric oxide synthase a target for chemoprevention?” Molecular Cancer Therapeutics, vol. 2, no. 8, pp. 815–823, 2003. View at Google Scholar · View at Scopus
  147. P. R. Eynott, D. A. Groneberg, G. Caramori et al., “Role of nitric oxide in allergic inflammation and bronchial hyperresponsiveness,” European Journal of Pharmacology, vol. 452, no. 1, pp. 123–133, 2002. View at Publisher · View at Google Scholar · View at Scopus
  148. A. H. Neufeld, S. I. Kawai, S. Das et al., “Loss of retinal ganglion cells following retinal ischemia: the role of inducible nitric oxide synthase,” Experimental Eye Research, vol. 75, no. 5, pp. 521–528, 2002. View at Publisher · View at Google Scholar · View at Scopus
  149. T. T. Hansel, S. A. Kharitonov, L. E. Donnelly et al., “A selective inhibitor of inducible nitric oxide synthase inhibits exhaled breath nitric oxide in healthy volunteers and asthmatics,” The FASEB Journal, vol. 17, no. 10, pp. 1298–1300, 2003. View at Google Scholar · View at Scopus
  150. H. F. Hodson, R. M. J. Palmer, D. A. Sawyer et al., “Enzyme inhibitors,” US patent WO9534534(A1), 1995.
  151. A. R. Baydoun, J. Bertran, S. Thakur, J. Dawson, M. Palacín, and R. G. Knowles, “y+ LAT-1 mediates transport of the potent and selective iNOS inhibitor, GW274150, in control J774 macrophages,” Amino Acids, vol. 31, no. 2, pp. 101–109, 2006. View at Publisher · View at Google Scholar · View at Scopus
  152. A. J. O'Brien, A. J. Wilson, R. Sibbald, M. Singer, and L. H. Clapp, “Temporal variation in endotoxin-induced vascular hyporeactivity in a rat mesenteric artery organ culture model,” British Journal of Pharmacology, vol. 133, no. 3, pp. 351–360, 2001. View at Google Scholar · View at Scopus
  153. S. Mattiussi, C. Lazzari, S. Truffa et al., “Homeodomain interacting protein kinase 2 activation compromises endothelial cell response to laminar flow: protective role of p21waf1,cip1,sdi1,” PLoS One, vol. 4, no. 8, Article ID e6603, 2009. View at Publisher · View at Google Scholar · View at Scopus
  154. P. K. Chatterjee, E. O. Kvale, N. S. A. Patel, and C. Thiemermann, “GW274150 inhibits nitric oxide production by primary cultures of rat proximal tubular cells,” Medical Science Monitor, vol. 9, no. 10, pp. BR357–BR362, 2003. View at Google Scholar · View at Scopus
  155. S. Arnhold, A. Faßbender, F. J. Klinz et al., “NOS-II is involved in early differentiation of murine cortical, retinal and ES cell-derived neurons - An immunocytochemical and functional approach,” International Journal of Developmental Neuroscience, vol. 20, no. 2, pp. 83–92, 2002. View at Publisher · View at Google Scholar · View at Scopus
  156. J. De Alba, N. M. Clayton, S. D. Collins, P. Colthup, I. Chessell, and R. G. Knowles, “GW274150, a novel and highly selective inhibitor of the inducible isoform of nitric oxide synthase (iNOS), shows analgesic effects in rat models of inflammatory and neuropathic pain,” Pain, vol. 120, no. 1-2, pp. 170–181, 2006. View at Publisher · View at Google Scholar · View at Scopus
  157. M. C. McDonald, M. Izumi, S. Cuzzocrea, and C. Thiemermann, “A novel, potent and selective inhibitor of the activity of inducible nitric oxide synthase (GW274150) reduces the organ injury in hemorrhagic shock,” Journal of Physiology and Pharmacology, vol. 53, no. 4 I, pp. 555–569, 2002. View at Google Scholar · View at Scopus
  158. S. Cuzzocrea, P. K. Chatterjee, E. Mazzon et al., “Beneficial effects of GW274150, a novel, potent and selective inhibitor of iNOS activity, in a rodent model of collagen-induced arthritis,” European Journal of Pharmacology, vol. 453, no. 1, pp. 119–129, 2002. View at Publisher · View at Google Scholar · View at Scopus
  159. P. K. Chatterjee, N. S. A. Patel, A. Sivarajah et al., “GW274150, a potent and highly selective inhibitor of iNOS reduces experimental renal ischemia/reperfusion injury,” Kidney International, vol. 63, no. 3, pp. 853–865, 2003. View at Publisher · View at Google Scholar · View at Scopus
  160. L. Dugo, S. Marzocco, E. Mazzon et al., “Effects of GW274150, a novel and selective inhibitor of iNOS activity, in acute lung inflammation,” British Journal of Pharmacology, vol. 141, no. 6, pp. 979–987, 2004. View at Publisher · View at Google Scholar · View at Scopus
  161. R. Di Paola, E. Mazzon, N. S. A. Patel et al., “Beneficial effects of GW274150 treatment on the development of experimental colitis induced by dinitrobenzene sulfonic acid,” European Journal of Pharmacology, vol. 507, no. 1–3, pp. 281–289, 2005. View at Publisher · View at Google Scholar · View at Scopus
  162. L. Broom, L. Marinova-Mutafchieva, M. Sadeghian, J. B. Davis, A. D. Medhurst, and D. T. Dexter, “Neuroprotection by the selective iNOS inhibitor GW274150 in a model of Parkinson disease,” Free Radical Biology and Medicine, vol. 50, no. 5, pp. 633–640, 2011. View at Publisher · View at Google Scholar · View at Scopus
  163. D. Singh, D. Richards, R. G. Knowles et al., “Selective inducible nitric oxide synthase inhibition has no effect on allergen challenge in asthma,” American Journal of Respiratory and Critical Care Medicine, vol. 176, no. 10, pp. 988–993, 2007. View at Publisher · View at Google Scholar · View at Scopus
  164. J. E. Palmer, F. L. Guillard, B. E. Laurijssens, A. L. Wentz, R. M. Dixon, and P. M. Williams, “A randomised, single-blind, placebo-controlled, adaptive clinical trial of GW274150, a selective iNOS inhibitor, in the treatment of acute migraine,” Cephalalgia, vol. 29, no. 1, p. 124, 2009. View at Google Scholar
  165. H. O. Høivik, B. E. Laurijssens, L. O. Harnisch et al., “Lack of efficacy of the selective iNOS inhibitor GW274150 in prophylaxis of migraine headache,” Cephalalgia, vol. 30, no. 12, pp. 1458–1467, 2010. View at Publisher · View at Google Scholar · View at Scopus
  166. T. D. Rogerson, C. F. Wilkinson, and K. Hetarski, “Steric factors in the inhibitory interaction of imidazoles with microsomal enzymes,” Biochemical Pharmacology, vol. 26, no. 11, pp. 1039–1042, 1977. View at Publisher · View at Google Scholar · View at Scopus
  167. D. D. Rees, R. M. J. Palmer, and S. Moncada, “Role of endothelium-derived nitric oxide in the regulation of blood pressure,” Proceedings of the National Academy of Sciences of the United States of America, vol. 86, no. 9, pp. 3375–3378, 1989. View at Google Scholar · View at Scopus
  168. D. R. Cheshire, A. Åberg, G. M. K. Andersson et al., “The discovery of novel, potent and highly selective inhibitors of inducible nitric oxide synthase (iNOS),” Bioorganic and Medicinal Chemistry Letters, vol. 21, no. 8, pp. 2468–2471, 2011. View at Publisher · View at Google Scholar · View at Scopus
  169. T. Fullmer, “Rethinking mechanisms of drug discovery,” SciBX, vol. 4, no. 27, 2011. View at Google Scholar
  170. H. Huang, P. Martásek, L. J. Roman, and R. B. Silverman, “Synthesis and evaluation of peptidomimetics as selective inhibitors and active site probes of nitric oxide synthases,” Journal of Medicinal Chemistry, vol. 43, no. 15, pp. 2938–2945, 2000. View at Publisher · View at Google Scholar · View at Scopus
  171. S. Ekins, J. Mestres, and B. Testa, “In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling,” British Journal of Pharmacology, vol. 152, no. 1, pp. 9–20, 2007. View at Publisher · View at Google Scholar · View at Scopus
  172. R. V. C. Guido, G. Oliva, and A. D. Andricopulo, “Virtual screening and its integration with modern drug design technologies,” Current Medicinal Chemistry, vol. 15, no. 1, pp. 37–46, 2008. View at Publisher · View at Google Scholar · View at Scopus
  173. L. Hoffer, J. P. Renaud, and D. Horvath, “Fragment-based drug design: computational and experimental state of the art,” Combinatorial Chemistry and High Throughput Screening, vol. 14, no. 6, pp. 500–520, 2011. View at Publisher · View at Google Scholar · View at Scopus
  174. A. C. Tinker, H. G. Beaton, N. Boughton-Smith et al., “1,2-Dihydro-4-quinazolinamines: potent, highly selective inhibitors of inducible nitric oxide synthase which show antiinflammatory activity in vivo,” Journal of Medicinal Chemistry, vol. 46, no. 6, pp. 913–916, 2003. View at Publisher · View at Google Scholar · View at Scopus
  175. H. Ji, B. Z. Stanton, J. Igarashi et al., “Minimal pharmacophoric elements and fragment hopping, an approach directed at molecular diversity and isozyme selectivity. Design of selective neuronal nitric oxide synthase inhibitors,” Journal of the American Chemical Society, vol. 130, no. 12, pp. 3900–3914, 2008. View at Publisher · View at Google Scholar · View at Scopus
  176. S. Ekins, J. Mestres, and B. Testa, “In silico pharmacology for drug discovery: applications to targets and beyond,” British Journal of Pharmacology, vol. 152, no. 1, pp. 21–37, 2007. View at Publisher · View at Google Scholar · View at Scopus
  177. H. Ji, H. Li, M. Flinspach, T. L. Poulos, and R. B. Silverman, “Computer modeling of selective regions in the active site of nitric oxide synthases: implication for the design of isoform-selective inhibitors,” Journal of Medicinal Chemistry, vol. 46, no. 26, pp. 5700–5711, 2003. View at Publisher · View at Google Scholar · View at Scopus
  178. L. G. Fröhlich, P. Kotsonis, H. Traub et al., “Inhibition of neuronal nitric oxide synthase by 4-amino pteridine derivatives: structure-activity relationship of antagonists of (6R)-5,6,7,8- tetrahydrobiopterin cofactor,” Journal of Medicinal Chemistry, vol. 42, no. 20, pp. 4108–4121, 1999. View at Publisher · View at Google Scholar · View at Scopus
  179. H. Matter, P. Kotsonis, O. Klingler et al., “Structural requirements for inhibition of the neuronal nitric oxide synthase (NOS-I): 3D-QSAR analysis of 4-oxo- and 4-amino-pteridine-based inhibitors,” Journal of Medicinal Chemistry, vol. 45, no. 14, pp. 2923–2941, 2002. View at Publisher · View at Google Scholar · View at Scopus